CytomX Therapeutics, Inc. (CTMX)

NASDAQ: CTMX · Real-Time Price · USD

Compare

5.43

-0.13 (-2.34%)

At close: Feb 12, 2026, 4:00 PM EST

5.42

-0.01 (-0.18%)

After-hours: Feb 12, 2026, 7:55 PM EST

CytomX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	113.63	138.1	101.21	53.16	37.31	68.43
Revenue Growth (YoY)	-10.26%	36.45%	90.38%	42.48%	-45.47%	154.36%
Gross Profit	113.63	138.1	101.21	53.16	37.31	68.43
Selling, General & Admin	28.1	29.73	30.02	40.45	39.16	36.03
Research & Development	62.28	83.38	77.68	106.55	114.19	112.94
Operating Expenses	90.38	113.11	107.7	147	153.35	148.97
Operating Income	23.25	25	-6.48	-93.84	-116.04	-80.54
Interest & Investment Income	5	7.14	9.84	1.68	0.26	1.84
Currency Exchange Gain (Loss)	0.01	-0.04	-0.03	0.34	-0.08	-0.03
EBT Excluding Unusual Items	28.26	32.09	3.32	-91.82	-115.87	-78.73
Merger & Restructuring Charges	-	-	-	-7.5	-	-
Pretax Income	28.26	32.09	3.32	-99.32	-115.87	-78.73
Income Tax Expense	0.25	0.22	3.89	-	-	-13.91
Net Income	28.02	31.87	-0.57	-99.32	-115.87	-64.82
Net Income to Common	28.02	31.87	-0.57	-99.32	-115.87	-64.82
Shares Outstanding (Basic)	117	84	74	66	64	46
Shares Outstanding (Diluted)	118	85	74	66	64	46
Shares Change (YoY)	41.04%	14.82%	12.27%	2.48%	39.01%	1.79%
EPS (Basic)	0.24	0.38	-0.01	-1.51	-1.81	-1.40
EPS (Diluted)	0.24	0.38	-0.01	-1.51	-1.81	-1.40
Free Cash Flow	-72.35	-86.54	-56.88	-112.53	-120.64	2.95
Free Cash Flow Per Share	-0.61	-1.02	-0.77	-1.71	-1.88	0.06
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	20.46%	18.10%	-6.41%	-176.50%	-311.00%	-117.70%
Profit Margin	24.66%	23.08%	-0.56%	-186.82%	-310.54%	-94.73%
Free Cash Flow Margin	-63.67%	-62.66%	-56.19%	-211.67%	-323.33%	4.31%
EBITDA	24.53	26.76	-4.31	-91.39	-113.34	-77.97
EBITDA Margin	21.58%	19.38%	-4.26%	-171.91%	-	-113.94%
D&A For EBITDA	1.28	1.77	2.18	2.44	2.71	2.57
EBIT	23.25	25	-6.48	-93.84	-116.04	-80.54
EBIT Margin	20.46%	18.10%	-6.41%	-176.50%	-	-117.70%
Effective Tax Rate	0.87%	0.70%	117.12%	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q